Loading clinical trials...
Loading clinical trials...
Combination of Brutons Tyrosine Kinase (BTK) Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant Acute Myeloid Leukemia (AML)
Conditions
Interventions
Ibrutinib
Locations
1
China
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Start Date
August 1, 2018
Primary Completion Date
August 1, 2022
Completion Date
September 1, 2023
Last Updated
August 22, 2018
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT04628026
NCT06484062
Lead Sponsor
Nanfang Hospital, Southern Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions